What if fighting cancer didn’t require weeks of hospital visits, intense chemotherapy, and lab-grown immune cells but just a single shot?
For patients with aggressive blood cancers like leukemia and lymphoma, CAR T-cell therapy has offered hope. It works by genetically modifying a patient’s own immune cells to recognize and attack cancer. But the treatment is complex, time-consuming, and often out of reach for many both medically and financially. Each round can cost hundreds of thousands of dollars and take weeks to prepare.
Now, researchers may have found a way to rewrite that story. Using the same mRNA technology behind COVID-19 vaccines, scientists have developed a shot that turns a person’s T cells into cancer-killers inside the body no lab, no extraction, no reinfusion required. In animal studies, this approach not only shrank tumors but did so with fewer side effects and a fraction of the effort.
It’s not science fiction. It’s the next step in cancer immunotherapy and it could change how we treat cancer for good. Here’s how it works.
What is CAR T-Cell Therapy and Why It’s Not for Everyone
CAR T-cell therapy has become a powerful weapon against certain blood cancers. It’s part of a broader approach called immunotherapy, which uses the body’s own immune system to fight disease. But CAR T therapy is different it doesn’t just boost immune activity. It re-engineers it.
Here’s how it works: Doctors begin by collecting a patient’s T cells the immune system’s frontline soldiers. Those cells are sent to a specialized lab, where they’re genetically modified to carry something called a chimeric antigen receptor, or CAR. This receptor helps the T cells recognize specific markers on cancer cells. Once engineered, the CAR T cells are grown into the millions and infused back into the patient to seek out and destroy cancer.
It’s often described as a “living drug” because these cells keep working and multiplying in the body long after the infusion.
This process has delivered remarkable outcomes, especially for patients with cancers like acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma types that are often resistant to standard treatments. In some clinical trials, CAR T therapy has sent these cancers into remission for years, even when nothing else worked. But despite its success, traditional CAR T-cell therapy comes with major limitations:
- Time: The process from collecting cells to modifying and reinfusing them takes 3 to 5 weeks. That’s too long for patients with fast-progressing disease.
- Cost: Each treatment can run upwards of $400,000, not including hospital stays or supportive care.
- Toxicity: Patients often need chemotherapy to “make space” for the engineered cells. And once infused, those cells can cause serious side effects, like cytokine release syndrome (CRS), which can trigger dangerously high fevers, low blood pressure, or organ damage.
- Access: Only specialized cancer centers offer the therapy, making it logistically out of reach for many patients.
Dr. James Kochenderfer of the National Cancer Institute, who has led multiple CAR T trials, summed it up: “Before CAR T-cell therapies became available, many patients with advanced lymphomas were virtually untreatable. But that doesn’t mean this treatment works for everyone or that everyone can get it.”
The Game Changer: mRNA That Reprograms Immune Cells On-Site
Scientists created a specialized shot using mRNA bundled in lipid nanoparticles. These nanoparticles are engineered to target T cells in the bloodstream by binding to a protein called CD5, found on the surface of most T cells. Once injected, the lipid bubble fuses with the T cell, delivering the mRNA payload inside. The mRNA carries genetic instructions that teach the T cell to produce a custom receptor one that’s programmed to recognize and attack cancer cells.
The idea isn’t entirely new mRNA vaccines, like those developed for COVID-19, also deliver genetic instructions into the body. But the delivery in this cancer-fighting shot is far more precise. Instead of being absorbed randomly by nearby cells at the injection site, these nanoparticles are actively targeted to immune cells, allowing a more focused and effective transformation.
In a Stanford-led study published in Proceedings of the National Academy of Sciences, researchers used this approach to generate CAR T cells in mice with B-cell lymphoma a cancer of the immune system. Within hours of injection, the modified T cells began producing receptors that latch onto CD19, a protein found on the surface of cancerous B cells. These engineered cells homed in on tumors and started destroying the cancer from the inside out.
The same study also incorporated a second protein that made the newly created CAR T cells visible through PET scans. This allowed researchers to track their movement and activity throughout the body—something traditional CAR T therapy doesn’t offer.
This in vivo approach avoids one of the most burdensome steps in standard CAR T therapy: preconditioning chemotherapy. Normally, patients undergo lymphodepleting treatment to clear space for the incoming CAR T cells. In the mRNA shot model, no such depletion is required. The T cells are already in the body they’re simply being reprogrammed where they are.
Perhaps most significantly, the therapy isn’t a one-and-done deal. The mRNA shot can be given multiple times, each dose prompting a fresh wave of cancer-targeting cells. “We didn’t see any toxicity, even with a fairly large number of injections,” said Dr. Katherine Ferrara, senior author of the study. “It could theoretically be repeated multiple times to enhance the cancer-killing effect.”
In preclinical trials, this new method was able to produce millions of CAR T cells in each mouse numbers comparable to the cell counts achieved with lab-grown therapy. And it did so without triggering the severe side effects often associated with traditional CAR T-cell infusions.
What the Research Shows (So Far)
In laboratory animals, including mice, rats, and monkeys, the injectable mRNA therapy showed it could generate millions of functional CAR T cells directly inside the body. These cells weren’t just detectable they were effective. In one Stanford-led study involving mice with B-cell lymphoma, 6 out of 8 treated animals were completely tumor-free 60 days after the start of treatment. The remaining two had tumors that stopped growing and remained under control.
One of the key advantages was the ability to track the modified T cells in real time. Researchers included a second mRNA sequence that produced a PET-scan-visible protein, allowing them to confirm that the newly engineered cells were migrating to tumors, infiltrating them, and remaining active.
“We can see these in situ-generated CAR T cells infiltrating the tumors after repeated dosing,” said lead author Dr. Nisi Zhang. “And we saw tumor-free survival in 75% of the mice at the end of the study.”
The effectiveness wasn’t the only standout feature. The treatment was also remarkably well-tolerated. Even after multiple injections up to 18 doses researchers reported no signs of toxicity. That’s a stark contrast to conventional CAR T-cell therapy, which often causes serious side effects like cytokine release syndrome (CRS) and neurological issues (ICANS) that can require hospitalization and intensive care.
Another major finding: no need for preconditioning chemotherapy. Traditional CAR T therapy often starts with a round of chemo to temporarily weaken the patient’s immune system, allowing the lab-made cells to expand. But in these animal trials, the mRNA-generated CAR T cells multiplied on their own without help and did so quickly.
Importantly, the number of cancer-killing cells generated in vivo reached around 3 million per animal, which is roughly on par with the number used in traditional CAR T therapy for humans. These cells were not just present they were active, specific, and sustained their tumor-fighting activity over several weeks.
What makes these results especially compelling is the potential for repeat dosing. With conventional CAR T, patients typically receive a single infusion due to the risk of immune-related toxicity. But with this mRNA method, the therapy can be given in multiple rounds without triggering harmful immune reactions, allowing for fine-tuned, ongoing treatment.
How This Compares to Traditional CAR T-Cell Therapy
The traditional CAR T-cell approach has changed the game for blood cancer treatment but it’s far from perfect. Comparing it side by side with the new in vivo mRNA method highlights just how much ground this new approach could cover in terms of speed, safety, and scalability.
1. Process and Production
Traditional CAR T-cell therapy requires a multi-step process:
- Blood is drawn from the patient.
- T cells are isolated, shipped to a lab, and genetically modified to express chimeric antigen receptors (CARs).
- The modified cells are expanded to hundreds of millions.
- After 3–5 weeks, the final product is sent back to be infused into the patient.
By contrast, the mRNA approach eliminates the lab altogether. A shot containing lipid nanoparticles and mRNA is injected directly into the bloodstream. The patient’s own T cells absorb the mRNA and become cancer-fighters on-site often within hours.
2. Cost and Accessibility
Conventional CAR T-cell therapy can cost upwards of $400,000 per patient, not including hospitalization and supportive care. Part of the cost comes from the personalized nature of the treatment and the need for FDA-approved manufacturing facilities.
The in vivo mRNA method has the potential to dramatically reduce costs. It skips the need for cell extraction, lab engineering, and reinfusion, cutting down on the most expensive parts of the process. If clinical trials succeed, it could become an “off-the-shelf” immunotherapy, potentially making advanced treatment more accessible to patients worldwide.
3. Time to Treatment
Speed is critical for many patients with aggressive cancers. Traditional CAR T therapy takes 3 to 5 weeks, during which the cancer may continue to progress. Preconditioning chemotherapy is also required to prepare the body for the incoming cells.
The mRNA shot could be administered in a matter of hours. And because it doesn’t require lymphodepleting chemotherapy beforehand, it could be suitable even for patients who are too sick for standard prep protocols.
4. Safety and Repeatability
Conventional CAR T therapy can cause serious side effects, especially cytokine release syndrome (CRS) and immune-related neurotoxicity (ICANS). These complications are sometimes life-threatening and require emergency intervention.
In contrast, the mRNA method showed minimal toxicity in animal models even with repeated doses. Researchers were able to deliver up to 18 injections without triggering harmful effects. This opens the door for repeat dosing, fine-tuning treatment over time something that isn’t possible with traditional CAR T.
5. Monitoring and Control
One of the biggest unknowns with traditional CAR T-cell therapy is what happens after infusion. Monitoring activity inside the body is difficult, and off-target effects can be hard to detect until symptoms appear.
The in vivo mRNA technique solves this by including a tracer protein in the mRNA, making it possible to track the engineered T cells using standard PET scans. That allows doctors to monitor in real time where the cells are going, how many are being made, and whether they’re targeting the tumor as expected.
Could This Technology Go Beyond Cancer?
In diseases like systemic lupus erythematosus (SLE), the immune system mistakenly attacks the body’s own tissues. A key player in this dysfunction? Rogue B cells the same type of cells targeted by CAR T-cell therapy in cancer treatment. In fact, early studies have shown that depleting B cells using CAR T technology can induce long-term remission in severe, treatment-resistant lupus cases.
The new mRNA-based method could make this process simpler and safer. Instead of needing to extract and engineer T cells in a lab something that would be too intensive for many autoimmune patients this technique could deliver the therapy with a shot, possibly avoiding many of the side effects and logistical barriers tied to traditional CAR T.
Researchers are already exploring this idea. Since the lipid nanoparticles can be tuned to carry different mRNA “instructions”, the platform is modular. That means the same basic delivery method could be used to:
- Program T cells to eliminate malfunctioning B cells in lupus, multiple sclerosis, or rheumatoid arthritis.
- Silence or reprogram immune cells involved in organ rejection post-transplant.
- Potentially modulate chronic inflammation by targeting specific immune cell pathways.
What makes this approach especially promising is its temporary, non-integrating nature. Unlike DNA-based gene editing tools that permanently alter the genome, mRNA doesn’t make lasting changes. It delivers instructions that eventually degrade naturally, offering a built-in safety switch critical for diseases that might require periodic or targeted immune recalibration, not a permanent immune overhaul.
There’s even speculation about using mRNA-engineered T cells to treat viral infections or clear fibrotic tissue in conditions like heart failure or chronic liver disease. One mouse study showed that delivering modified mRNA using lipid nanoparticles to cardiac tissue could reverse fibrosis and restore heart function.
A Shot at Changing Everything
This new mRNA approach isn’t just a scientific advance it’s a rethinking of how we fight disease. By turning immune cells into cancer killers inside the body, researchers may be removing the biggest barriers that have kept CAR T-cell therapy out of reach for so many: time, cost, complexity, and risk.
Animal studies have shown that this method can be safe, fast, and remarkably effective. But as with any early-stage breakthrough, cautious optimism is essential. Human trials still need to confirm whether these results translate to real-world outcomes in patients. Until then, this is not a treatment yet but it is a glimpse into what could become a new standard of care.
The idea that a single injection could train your body to fight cancer or even calm an overactive immune system—isn’t science fiction anymore. It’s a sign of where medicine is heading: targeted, personalized, and possibly far less invasive than anything we’ve seen before.
For now, patients and caregivers should keep an eye on this evolving space. Ask questions. Follow the trials. Be wary of hype—but stay hopeful. Because if this technology delivers on its early promise, it could change how we treat cancer and immune-related diseases for good.
Source:
- Zhang, N., Seo, J. W., Robinson, E., Rivera-Rodriguez, A., Wang, J., Guo, Y., Czerwinski, D. K., Kim, H. R., Tumbale, S. K., Raie, M. N., Jan, B. L., Engudar, G., Sallets, A., Minn, I., Pomper, M. G., Levy, R., & Ferrara, K. W. (2025). Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging. Proceedings of the National Academy of Sciences, 122(24). https://doi.org/10.1073/pnas.2504950122
